青岛海尔生物医疗股份有限公司关于以集中竞价交易方式回购公司股份的进展公告

Group 1 - The company has approved a share repurchase plan to buy back its issued A-shares using its own funds through the Shanghai Stock Exchange, with a maximum repurchase price of 50 RMB per share and a total repurchase amount between 100 million RMB and 200 million RMB within 12 months [2][5] - Following the annual equity distribution in 2024, the maximum repurchase price was adjusted to 49.5367 RMB per share starting June 6, 2025 [3] - As of July 31, 2025, the company has repurchased a total of 1,845,488 shares, accounting for 0.5804% of the total share capital, with a total expenditure of approximately 59.25 million RMB [4] Group 2 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [6]